NALIRIFOX as Induction Therapy in LAPC
This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer.
| Condition(s) | Pancreatic Ductal Adenocarcinoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer. |
| Who can participate | Inclusion Criteria: 1. Age ≥ 18 years old, ≤ 70 years old, male or female; 2. Understand the objectives and benefits and risks of the clinical trial, voluntarily participate in and sign the informed consent form; 3. ECOG score 0-1; 4. The subject had histopathologically or cytologically confirmed type of pancreatic ductal adenocarcinoma 5. Local progression according to the 2022 CSCO guidelines; 6. Initial subjects with locally advanced pancreatic cancer who have not undergone resection of pancreatic tumor (except open exploration or internal drainage surgery), chemotherapy, targeted, or immunotherapy. 7. At least one measurable pancreatic lesion per RECIST 1.1 criteria; 8. Expected survival time ≥ 3 months. 9. Heart, lung, liver, kidney and other major organ functions are basically normal |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Locations | Nanjing, Jiangsu, China |
| Start date | 2023-12-25 |
| NCT ID | NCT06467565 |
| Official listing | https://clinicaltrials.gov/study/NCT06467565 |